ALS Untangled does not recommend off-label perampanel for ALS
Original source
Perampanel (opens in a new tab)ALS Untangled does not recommend using perampanel off label for amyotrophic lateral sclerosis (ALS) at this time. The group says human evidence is limited and notes safety concerns, including increased fall risk and serious psychiatric adverse effects.
Why this matters
This is relevant to people with ALS and clinicians considering perampanel, a seizure medicine, outside its approved use. The review does not establish a treatment benefit for ALS, and its recommendation is to wait for results from ongoing clinical trials.
Limitations and context
The evidence described in this 2019 expert review is limited. It includes a single flawed mouse study, limited human data, and the failure of the related drug talampanel in ALS clinical trials. The review was an independent expert assessment, not a new clinical trial, and ongoing perampanel trials were still awaited.